Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Partitioning of TSE infectivity during ethanol fractionation of human plasma.

Gregori L, Maring JA, MacAuley C, Dunston B, Rentsch M, Kempf C, Rohwer RG.

Biologicals. 2004 Mar;32(1):1-10.

PMID:
15026020
2.

Prion-removal capacity of chromatographic and ethanol precipitation steps used in the production of albumin and immunoglobulins.

Thyer J, Unal A, Thomas P, Eaton B, Bhashyam R, Ortenburg J, Uren E, Middleton D, Selleck P, Maher D.

Vox Sang. 2006 Nov;91(4):292-300.

PMID:
17105604
4.

TSE clearance during plasma products separation process by Gradiflow(TM).

Wang K, Johnson A, Obradovic M, Anderson G, Maclean C, Nair H.

Biologicals. 2005 Jun;33(2):87-94. Epub 2005 Apr 7.

PMID:
15939286
5.

Elimination capacity of a TSE-model agent in the manufacturing process of Alphanate/Fanhdi, a human factor VIII/VWF complex concentrate.

Diez JM, Caballero S, Belda FJ, Otegui M, Gajardo R, Jorquera JI.

Haemophilia. 2009 Nov;15(6):1249-57. doi: 10.1111/j.1365-2516.2009.02067.x. Epub 2009 Jun 26.

PMID:
19563480
6.

Partitioning of human and sheep forms of the pathogenic prion protein during the purification of therapeutic proteins from human plasma.

Stenland CJ, Lee DC, Brown P, Petteway SR Jr, Rubenstein R.

Transfusion. 2002 Nov;42(11):1497-500.

PMID:
12421224
7.

Capacity of the manufacturing process of Flebogamma(®) DIF, a new human high purity intravenous immunoglobulin, to remove a TSE model-agent.

Diez JM, Caballero S, Belda F, Otegui M, Gajardo R, Jorquera JI.

Biologicals. 2010 Nov;38(6):670-4. doi: 10.1016/j.biologicals.2010.08.003. Epub 2010 Sep 22.

PMID:
20863716
8.

CJD PrPsc removal by nanofiltration process: application to a therapeutic immunoglobulin solution (Lymphoglobuline).

Truchot L, Arnaud T, Bloy C, Perret-Liaudet A.

Biologicals. 2006 Sep;34(3):227-31. Epub 2006 Feb 20.

PMID:
16490361
9.

A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins.

Lee DC, Stenland CJ, Miller JL, Cai K, Ford EK, Gilligan KJ, Hartwell RC, Terry JC, Rubenstein R, Fournel M, Petteway SR Jr.

Transfusion. 2001 Apr;41(4):449-55. Erratum in: Transfusion 2001 Aug;41(8):1079.

PMID:
11316893
10.

Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the prion protein.

Lee DC, Stenland CJ, Hartwell RC, Ford EK, Cai K, Miller JL, Gilligan KJ, Rubenstein R, Fournel M, Petteway SR Jr.

J Virol Methods. 2000 Jan;84(1):77-89.

PMID:
10644089
11.

Current strategies to prevent transmission of prions by human plasma derivatives.

Burnouf T, Padilla A.

Transfus Clin Biol. 2006 Nov;13(5):320-8. Epub 2007 Jan 23.

PMID:
17254822
12.

Impacts and concerns for vCJD in blood transfusion: current status.

MacGregor IR, Prowse CV.

Curr Mol Med. 2004 Jun;4(4):361-73. Review.

PMID:
15354867
13.

Removal of exogenous (spiked) and endogenous prion infectivity from red cells with a new prototype of leukoreduction filter.

Sowemimo-Coker S, Kascsak R, Kim A, Andrade F, Pesci S, Kascsak R, Meeker C, Carp R, Brown P.

Transfusion. 2005 Dec;45(12):1839-44. Erratum in: Transfusion. 2006 Feb;46(2):313.

PMID:
16371036
14.
15.

Safety procedures of coagulation factors.

Jorquera JI.

Haemophilia. 2007 Dec;13 Suppl 5:41-6. doi: 10.1111/j.1365-2516.2007.01578.x.

PMID:
18078396
16.

Prion diseases: current understanding of epidemiology and pathogenesis, and therapeutic advances.

Caramelli M, Ru G, Acutis P, Forloni G.

CNS Drugs. 2006;20(1):15-28. Review.

PMID:
16396521
17.

Pall leukotrap affinity prion-reduction filter removes exogenous infectious prions and endogenous infectivity from red cell concentrates.

Sowemimo-Coker SO, Pesci S, Andrade F, Kim A, Kascsak RB, Kascsak RJ, Meeker C, Carp R.

Vox Sang. 2006 May;90(4):265-75.

PMID:
16635068
18.

A 25 nm virion is the likely cause of transmissible spongiform encephalopathies.

Manuelidis L.

J Cell Biochem. 2007 Mar 1;100(4):897-915. Review.

PMID:
17044041
19.

Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products.

Foster PR, Welch AG, McLean C, Griffin BD, Hardy JC, Bartley A, MacDonald S, Bailey AC.

Vox Sang. 2000;78(2):86-95.

PMID:
10765143
20.

Prion diseases and emerging prion diseases.

Yokoyama T, Mohri S.

Curr Med Chem. 2008;15(9):912-6. Review.

PMID:
18473798

Supplemental Content

Support Center